In a phase 1b randomised crossover trial in 22 adults with long-standing type 1 diabetes, the SSTR2 antagonist ZT-01 (3 mg or 20 mg) raised glucagon responses during insulin-induced level 1 and 2 hypoglycaemia vs placebo, with no drug-related adverse events.
RCTn = 24
Abitbol et al. Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study